Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X about a paper by Nicholas J. McNamee et al. published in Clinical Cancer Research:
“An attempt to discuss the correlation (or lack thereof) between ADCs and target expression, with a primary focus on some approved ADCs and CLDN18.2.
Bonus: open access! Important topic, some errors and imprecisions.”
Title: Predictive Biomarkers of Antibody-Drug Conjugate Efficacy for Solid Tumors: Current Challenges and the Potential Role of Quantitative Proteomics
Authors: Nicholas J. McNamee, Jia Liu, Rebecca C. Poulos, Adel T. Aref, Roger R. Reddel
Read the Full Article in Clinical Cancer Research.
More posts featuring Raffaele Colombo on OncoDaily.
